Polo-like kinase-1 (Plk1) has a pivotal role in cell proliferation and is considered a potential target for anticancer therapy. The noncatalytic polo-box domain (PBD) of Plk1 forms a phosphoepitope binding module for protein-protein interaction. Here, we report the identification of minimal phosphopeptides that specifically interact with the PBD of human PLK1, but not those of the closely related PLK2 and PLK3. Comparative binding studies and analyses of crystal structures of the PLK1 PBD in complex with the minimal phosphopeptides revealed that the C-terminal SpT dipeptide functions as a high-affinity anchor, whereas the N-terminal residues are crucial for providing specificity and affinity to the interaction. Inhibition of the PLK1 PBD by phosphothreonine mimetic peptides was sufficient to induce mitotic arrest and apoptotic cell death. The mode of interaction between the minimal peptide and PBD may provide a template for designing therapeutic agents that target PLK1.
The Plks are a conserved subfamily of serine-threonine protein kinases that have crucial roles in cell proliferation (reviewed in refs. 1,2). Plks are characterized by the presence of a highly conserved C-terminal PBD composed of the structurally related PB1 (residues 411-489 in PLK1) and PB2 (residues 511-592) motifs (reviewed in ref. 3) . Multiple forms of Plks, designated Plk1, Plk2 (or Snk), Plk3 (or Prk or Fnk) and Plk4 (or Sak), exist in mammals. Plk4 is the most distantly related member of the Plk subfamily; one of the two Plk4 variants, Sak-a, contains only the PB1 motif. Among the Plks, PLK1 has been studied most extensively because of its ability to override cellular checkpoints and induce genetic instability, leading to oncogenic transformation of human cells (reviewed in refs. 4, 5) . Not surprisingly, PLK1 is overexpressed in a broad spectrum of human cancers. Furthermore, interference with PLK1 function induces apoptotic cell death in most tumor cells, but not in normal cells, and reduces tumor growth in mouse xenograft models (reviewed in ref. 5) , suggesting that PLK1 could be targeted for therapeutic intervention against human cancers. In contrast to the role of Plk1 in cell proliferation and tumorigenesis, the two most closely related kinases, Plk2 and Plk3, seem to have a role in checkpoint-mediated cell-cycle arrest to ensure genetic stability and prevent oncogenic transformation 6, 7 . Thus, specific inhibition of PLK1, but not PLK2 or PLK3, could be important for anti-Plk1 cancer therapy.
The PBD of Plk1 has a crucial role in proper subcellular localization and mitotic functions of Plk1 (refs. 8-10) by interacting with serineor threonine-phosphorylated peptides with the invariable serine residue at the À1 position (S-p-S/T motif) 11 . Crystal structures of the PLK1 PBD in complex with artificial phosphopeptides optimized for PBD binding have revealed that the PB1 and PB2 motifs have identical b6a folds and form a heterodimeric phosphopeptide binding module 12, 13 . The phosphopeptide binds to a cleft formed between PB1 and PB2 and interacts with key amino acid residues from both polo boxes. His538 and Lys540 from PB2 are pivotal for electrostatic interactions with the negatively charged phosphate group of phosphorylated serine or threonine residue, whereas Trp414 from PB1 is crucial for the selection of serine at the À1 position (referred to hereafter as Ser-1, to indicate relative position from the Thr78 residue) by engaging in two hydrogen bonding interactions and van der Waals interactions with Ser-1 (refs. 12,13) . However, additional elements required for achieving a highly specific interaction between human PLK1 and its binding targets remain elusive. In this study, we took multifaceted approaches to determine the elements required for the interaction. Our results may provide new insights into the development of anti-PLK1 therapeutic agents.
RESULTS
Minimal phosphopeptides for PLK1 PBD binding PBIP1 (also known as MLF1IP, KLIP1, CENP-50 or CENP-U) was isolated as a PBD-interacting protein crucial for centromeric localization of PLK1 (ref. 14) and proper chromosome segregation [14] [15] [16] [17] . Further investigation of the PLK1-PBIP1 interaction showed that the PBD of PLK1 binds to the Thr78 region of PBIP1 in a phosphorylation-dependent manner 14 . To better understand the binding nature of this interaction, we synthesized various Thr78-phosphorylated (p-Thr78) peptides for in vitro binding analyses. A bead-immobilized 10-mer or 14-mer p-Thr78 peptide, but not the respective nonphosphorylated forms, precipitated PLK1 from mitotic HeLa cells as the major binding protein ( Supplementary Fig. 1a ). To determine a minimal sequence of the Thr78 motif required for the interaction, we carried out systematic deletions from the 10-mer p-Thr78 peptide (PLHSpTAIYAD) and tested the ability of various resulting peptides (Supplementary Table 1 ) to bind to PLK1. Notably, removal of all the amino acid residues C-terminal to the p-Thr78 residue did not diminish the level of PLK1 binding (Fig. 1a, below the N-terminal proline, had a much lower binding affinity to PLK1, whereas HSpT, which lacks both the N-terminal proline and leucine residues, did not show any detectable level of binding (Fig. 1a , below right). These results suggest that PLHSpT binds to PLK1 with high affinity and that, besides the SpT dipeptide, the N-terminal Pro-Leu motif is required to provide an additional level of affinity to the PBD.
To eliminate the bias of the deletion scheme in Figure 1a , we also tested whether other 5-mer peptides encompassing the SpT motif bind to PLK1 efficiently. LHSpTA, which lacks the N-terminal proline but bears the C-terminal alanine, bound to PLK1 almost as efficiently as did PLHSpT (Fig. 1b, left) . However, HSpTAI, which lacks both proline and leucine but instead bears two additional C-terminal residues after the SpT motif, bound to PLK1 only weakly (Fig. 1b,  right) , thus underlining the importance of the Leu-3 residue in the absence of the Pro-4 residue. Among the 4-mers, both LHSpT and HSpTA bound to PLK1 better than did SpTAI (Fig. 1c) . Comparative binding studies showed that the binding affinity of a short form of the previously characterized optimal PBD binding peptide (MQSpTPL) 13 is similar to that of the analogous p-Thr78 peptide (LHSpTAI; Fig. 1d ).
Specific, high-affinity binding of minimal p-Thr78 peptide
We tested the specificity of minimal p-Thr78 peptides against the PLK1 PBD. Similar to the initial 14-mer peptide, minimal p-Thr78 peptides precipitated PLK1 from cellular lysates containing similar levels of PLK1, PLK2 and PLK3 ( Fig. 2a and Supplementary Fig. 1b ). In contrast, the 6-mer optimal MQSpTPL peptide precipitated PLK2 with B27% the efficiency of PLK1 precipitation (Fig. 2a) , suggesting that the MQSpTPL possesses a substantially lower PLK1 specificity than does PLHSpT. Consistently, MQSpTPL, but not the p-Thr78 peptides, also precipitated PLK2 from lysates expressing PLK2 alone ( Supplementary  Fig. 1c) . Notably, although much shorter than the initial 14-mer peptide, the minimal p-Thr78 peptide PLHSpT showed undiminished PLK1 specificity and precipitated PLK1 as the only major binding protein from total cellular lysates (Fig. 2b) . Another 5-mer, LHSpTA, showed a similar but somewhat lower level of PLK1 affinity (Fig. 2b) . These results suggest that elements crucial for PLK1-binding affinity and specificity reside within these minimal sequences. Furthermore, PLHSpT efficiently bound to glutathione S-transferase (GST)-fused PBD (GST-PBD), but not to the respective GST-PBD(H538A, K540A) phosphate pincer mutant (Fig. 2c) , indicating that an intact phosphoepitope binding module is required for the interaction.
We next carried out isothermal titration calorimetry analyses with recombinant PLK1 PBD and quantified the binding parameters of the minimal p-Thr78 peptides. Among them, the 5-mer PLHSpT mediated the best binding contacts with the PBD (DH ¼ À14.5 kcal mol À1 ; Fig. 2d ), although its binding affinity overall (K d B0.45 mM) was equivalent to that of another 5-mer, LHSpTA. Under the same conditions, the synthetic optimal 6-mer peptide, MQSpTPL, bound to PBD with a K d of 0.534 mM ( Table 1) . Two other 6-mer peptides (PLHSpTA and LHSpTAI) had slightly higher affinities than did the 5-mer peptides, whereas two 4-mers (LHSpT and HSpTA) had much lower affinities ( Table 1) .
To test the specificity of the above peptides, we conducted calorimetry binding experiments with recombinant PLK2 PBD. Saturable binding was not observed in all cases and, as a result of the lack of a binding curve, values for binding enthalpy or binding affinity could not be extrapolated. However, a clear difference in the initial heats of interaction of the peptides was observed above the limits of detection (1 kcal mol À1 ) of the instrument. The two minimal p-Thr78 peptides, PLHSpT and LHSpTA, showed virtually no interactions with PLK2 (only baseline heats were detected), whereas MQSpTPL titrated into PLK2 PBD produced initial heats of À1.68 kcal mol À1 ( Table 2) . These results corroborate the specificity of the minimal p-Thr78 peptides for PLK1 over PLK2.
p-Thr78 peptide disrupts the PBD-Cdc25C interaction
We examined whether the minimal p-Thr78 peptides have the capacity to interfere with the interaction between PLK1 PBD and its physiological binding target, phosphorylated Cdc25C (p-Cdc25C). In agreement with the previous finding, GST-PBD precipitated p-Cdc25C, but not the unphosphorylated form, from mitotic HeLa lysates 13 ( Supplementary  Fig. 2a) . Addition of PLHSpT, but not the respective nonphosphorylated peptide, into the lysates disrupted the preformed PBD-p-Cdc25C complex in a phosphorylation-and concentration-dependent manner The other three structures were determined in this study.
( Supplementary Fig. 2b ). In a separate experiment, LHSpTA disrupted the preformed PBD-p-Cdc25C complex nearly as efficiently as did PLHSpT, whereas both LHSpT and HSpTA disrupted the complex weakly (Fig. 2e) . Furthermore, PLHSpT, but not the respective nonphosphorylated form, disrupted the in vivo PLK1-p-Cdc25C interaction (Fig. 2f) . Thus, p-Thr78 peptides inhibit the interaction between the PBD and its binding targets by competitively binding to the PBD.
The binding nature of the PLK1 PBD To investigate the binding nature of the minimal peptides to the PBD, we solved the crystal structures of the PLK1 PBD in complex with the phosphopeptides PLHSpT (hereafter referred to as PBD PL ) and PPHSpT (PBD PP ; to examine the importance of the N-terminal residue for the interaction) at 1.7-Å and at 2.3-Å resolution, respectively (Fig. 3a,b and Table 3 ). Additionally, we attempted to crystallize a complex by mixing the PBD (without phosphopeptide) and the kinase domain, each expressed and purified separately. However, the kinase domain precipitated, and only the PBD was found in a diffraction-quality crystal. This crystal form contained two PBD molecules per asymmetric unit, referred to as PBD S+G (with sulfate and glycerol) and PBD S (with sulfate only) for chains A and B, respectively (Fig. 3a) . We found several strong peaks of positive difference density in the F o À F c maps for PBD PL , PBD S+G and PBD S , which could not be interpreted as water molecules. These peaks were modeled as sulfate, glycerol and ethylene glycol molecules. PBD PL contained a glycerol molecule in the phosphopeptide binding cleft (Fig. 3a,b) , occupying a cavity formed by the phosphopeptide, two water molecules and PBD. The three hydroxyl groups of this glycerol molecule were involved in hydrogen bonding with the backbone carbonyls of the phosphopeptide and PBD, the phosphate group of p-Thr, and one of the water molecules. PBD S+G and PBD S contained a sulfate anion in the same pocket (Fig. 3a) , in the region normally occupied by the phosphate of p-Thr. We chose to model the density in this pocket as sulfate instead of phosphate given the presence of 0.3 M lithium sulfate in the crystallization medium. PBD S+G also contained a glycerol molecule in the phosphopeptide binding cleft (Fig. 3a) . This glycerol molecule was located at the À1 position, normally occupied by the serine residue when a phosphopeptide is in the binding cleft (Fig. 3a) . The L2 loop in PBD S was much less ordered than in the PBD S+G structure. Analysis of contacts with symmetry-related molecules showed that this difference in the degree of order observed in the L2 region is likely to be caused by crystal packing.
Role of N-terminal residues of the minimal p-Thr78 peptides Inspection of the structure of the PLHSpT-PBD complex revealed that, in addition to the previously described SpT-dependent interactions 12, 13 , the N-terminal proline residue is crucial for providing additional affinity to PBD binding by engaging in two discrete, yet interconnected, interactions. The carbonyl oxygen of the N-terminal proline residue was in polar contact (hydrogen bonding) with the guanidinium moiety of Arg516, whereas the pyrrolidine ring of the proline residue enhanced the interaction by docking into a shallow hydrophobic pocket generated by the surrounding Trp414 and Phe535 (Fig. 3a,b) . The importance of the latter interaction with the proline binding pocket was manifest by the observation that LHSpT, which can still form polar contact with Arg516 through the acetyl carbonyl N-terminal to the Leu-3 residue, showed B50-fold weaker binding than PLHSpT ( Table 1) . We directly showed a crucial role for the N-terminal proline residue in PBD binding in experiments with PPHSpT. The N-terminal proline at the À4 position of PPHSpT was flipped out of the proline binding pocket and was unable to generate the polar contact and hydrophobic interactions because the Pro-3 residue locks the backbone of the phosphopeptide in a conformation opposite to that of PLHSpT (Fig. 3c) . Consequently, PPHSpT showed a markedly lower (20-fold) binding affinity to PLK1 (Fig. 3d) . Moreover, MLHSpT, bearing Met-4 instead of Pro-4, showed a much lower level of PLK1 binding (Fig. 3e) , further highlighting the importance of the Pro-4 residue in stably binding into the pocket. Consistent with these observations, the Pro-4 residue in PMQSpTPL docked into the proline binding pocket 13 (Fig. 3c) , whereas, in the absence of the N-terminal Pro-4, the side chain of the free (unacetylated) N-terminal Met-3 in MQSpTPL extended into the pocket 12 (Fig. 3c) .
Notably, LHSpTA also showed a high PLK1 PBD binding affinity and specificity, even in the absence of the Pro-4 residue (Fig. 2a,b,d) . Analyses of the crystal structure of the PLK1 PBD in complex with LHSpTA (PBD LH ; Table 3) revealed that, similar to Leu-3 of PLHSpT, the N-terminal Leu-3 side chain of LHSpTA was directed into an intramolecular cavity and did not seem to be involved in interactions with surrounding PBD residues (Supplementary Fig. 3 ). The N-terminal acetyl carbonyl of LHSpTA was in polar contact with Arg516, thus substituting the interaction engaged by the carbonyl oxygen of the Pro-4 of PLHSpT. Because PLK2 and PLK3 possess a lysine residue at the position analogous to PLK1 Arg516, the polar contact observed in the two PLK1-specific peptides, PLHSpT and LHSpTA, is likely to be one of the major determinants of PLK1 PBD specificity.
Apart from the phosphopeptide backbone region of Leu-3, as mentioned above, the weak electron density (2F o À F c ) observed in the PBD PL structure ( Supplementary  Fig. 4 ) suggested that the leucine side chain region is disordered and may not be involved in interactions with PBD. However, mutation of the Leu-3 of PLHSpT to alanine greatly diminished the level of PLK1 binding, whereas mutation to glutamine did not alter the PLK1 affinity (Fig. 3d) .
We next examined the importance of the His-2 residue for PLK1 specificity. In the crystal structure, the side chain of the His-2 residue did not directly mediate contacts with PBD residues (Fig. 3a,b) . Notably, mutation of His-2 to glutamine substantially increased (24-fold) the level of PLK2 binding (Fig. 3d) .
In calorimetry experiments, titration of the PLQSpT mutant into PLK2 PBD produced initial heats of interaction on the order of À1.1 kcal mol À1 , compared to virtually baseline heats for the parent PLHSpT ( Table 2 ). This finding suggests that the mutant peptide mediates binding contacts with PLK2 PBD, whereas the parent peptide is selective only for PLK1 PBD.
Our results suggest that the N-terminal Pro-Leu motif at the À4 and À3 positions is crucial for high-affinity and high-specificity interactions with PLK1 PBD, whereas the histidine residue at the À2 position is important to assure an additional layer of PLK1 specificity (Fig. 3f) . These findings explain in part why MQSpTPL, bearing the N-terminal methionine for the proline binding pocket and lacking the crucial His-2 residue, has a low PLK1 specificity. In addition, the Thr78 residue in PBIP1 is followed by alanine in place of the commonly found proline residue, thus allowing a non-proline-directed kinase such as PLK1 to phosphorylate the Thr78 residue (Fig. 3f) .
Inhibition of PLK1 PBD function by p-Thr78 mimetic peptide
The PBD-dependent interactions with various S-p-S/T-containing targets are crucial for proper PLK1 localization. As expected, acute inhibition of CDC2, one of the major kinases that prime the PBDbinding sites, markedly diminished the level of PLK1 localization to the centrosomes and kinetochores in prometaphase cells ( Supplementary  Fig. 5 ). This observation prompted us to test whether the minimal p-Thr78 peptides can interfere with the function of PLK1 by disrupting its localization in vivo. Consistent with the PBD pull-down assays, PLHSpT, but not the respective nonphosphorylated peptide, efficiently inhibited the p-Thr78-dependent PBD interaction in vitro, whereas LHSpTA inhibited the PBD at a moderately lower level ( Supplementary  Fig. 6 ). Because the phosphate group of the Thr78 residue is strictly required for PBD binding but is susceptible to dephosphorylation by intracellular phosphatases, we synthesized a phosphatase-resistant p-Thr Values in parentheses correspond to the highest-resolution shell.
mimetic, (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab), in protected form and incorporated it into peptides in place of the p-Thr residue (Fig. 4a) . The bead-immobilized PLHS-Pmab precipitated PLK1, but not PLK2 or PLK3, from mitotic HeLa lysates as efficiently as did the PLHSpT peptide (Fig. 4a,b) . As would be expected if the binding were PBD dependent, a mutation of the invariably required Ser-1 residue to alanine (PLHA-Pmab; hereafter Pmab(S77A) for simplicity) abolished PLK1 binding. Furthermore, the PLHS-Pmab peptide, but not the Pmab(S77A) mutant, efficiently interfered with p-Thr78-dependent PLK1 PBD interaction (Fig. 4c) .
To examine the effect of the Pmab-containing mimetic peptide in vivo, and to overcome poor membrane permeability of a negatively charged peptide, we conducted microinjection studies using HeLa cells released from an S-phase block. As would be expected if the function of PLK1 PBD were inhibited, the Pmab peptide, but not the Pmab(S77A) or nonphosphorylated Thr78 peptides, induced mitotic arrest in B60% of the microinjected cells (Fig. 4d,e) . Reminiscent of the phenotype associated with loss of PBD function 10, 18 , B25% of the arrested population (n 4 180 cells) showed a chromosome congression defect (Fig. 4f ).
Owing to the increasing level of apoptotic cell death after a prolonged mitotic block, the total numbers of arrested cells began to shrink at later time points (Fig. 4e) . Consistent with these observations, the Pmab peptide, but not the Pmab(S77A) or nonphosphorylated Thr78 peptides, interfered with PLK1 localization at the centrosomes and kinetochores and diminished PLK1 fluorescence signals (Fig. 4f,g ) to a level similar to that observed after treatment with the CDC2 inhibitor BMI-1026 ( Supplementary Fig. 5 ). Although not as efficient as the PLHS-Pmab peptide, another type of 2-amino-4,4-difluoro-3-methyl-4-phosphobutanoic acid (F 2 Pmab)-containing mimetic, PLHS-F 2 Pmab-A, but not the respective F 2 Pmab(S77A) mutant, precipitated PLK1 ( Supplementary Fig. 7a ) and induced PLK1 delocalization and chromosome misalignment that led to mitotic arrest and apoptotic cell death ( Supplementary Fig. 7b-f) . These results indicate that inhibition of PBD by the p-Thr78 mimetic peptide is sufficient to interfere with subcellular localization and mitotic functions of PLK1. DISCUSSION PLK1 overexpression is closely associated with tumorigenesis in a wide range of human cancers. It is also associated with aggressive disease stage and poor patient survival in various types of cancers 5 , suggesting that PLK1 is a potential target for anticancer therapies. Over the years, efforts have been made to generate PLK1 inhibitors, resulting in several compounds (Boehringer Ingelheim 2536, GlaxoSmithKline compound 1, cyclapolin 1, DAP81 and ZK-thiazolidinone) developed to competitively inhibit the kinase activity of PLK1 (ref. 5). However, largely because of the structural similarities among the catalytic domains of all Plks and other related kinases, it has been difficult to generate PLK1-specific inhibitors. Because the noncatalytic PBD is found only in members of the Plk subfamily, development of inhibitors that target the PBD of PLK1 may be an alternative strategy for selectively targeting PLK1.
In conducting studies on the interaction between PLK1 and its physiological binding target, PBIP1, we identified minimal phosphopeptides derived from the Thr78 region of PBIP1 that show a high level of affinity and specificity for the PLK1 PBD. Similar to the defects associated with the expression of a dominant-negative PBD 10, 18 , inhibition of the PLK1 PBD function by nonhydrolyzable p-Thr78 mimetic peptides induced a chromosome congression defect that led to mitotic arrest and apoptotic cell death. Because interference with PLK1 function induces apoptosis in most tumor cells, but not in normal cells 5 , these findings suggest that inhibition of the PBD function is sufficient to interfere with tumor cell proliferation. Furthermore, our results provide the proof of principle that specific inhibition of PLK1 PBD is achievable by small mimetic peptides or their relevant compounds. SpT-dependent electrostatic interactions are crucial for the binding of optimal peptides (PMQSpTPL and MQSpTPL) to the PLK1 PBD 12, 13 . Comparative in vitro binding studies and analyses of the phosphopeptide binding pockets of PBD S+G and PBD S with PBD PL , PBD PP and PBD LH revealed that, in addition to the SpT motif of the phosphopeptide acting as a high-affinity anchor, the N-terminal residues provide additional binding affinity and specificity to the PLK1 PBD through at least three distinct interactions. First, the polar contact between the carbonyl oxygen N-terminal to the Leu-3 of PLHSpT or LHSpTA and the guanidinium moiety of Arg516 of PLK1 PBD provides a molecular basis for a high-affinity and high-specificity interaction. Unlike PLK1, both PLK2 and PLK3 possess a lysine residue (Lys607 and Lys568, respectively) at the position analogous to the PLK1 Arg516. Second, docking of the N-terminal Pro-4 side chain into the pocket generated by the surrounding Trp414 and Phe535 offers additional affinity and, probably, another layer of specificity to the interaction. The PBDs from both PLK2 and PLK3 possess lysine and tyrosine residues at positions corresponding to the PLK1 Arg516 and Phe535 residues, respectively; as a consequence, they may be unable to generate as favorable an environment to accommodate the N-terminal proline residue. Third, mutational analyses of PLHSpT suggest that the His-2 residue is also crucial in determining PLK1 PBD specificity. Because the Nd1 of His-2 was involved in a hydrogen bond with the carbonyl oxygen of Ser-1, one possibility is that the hydrogen bond between these two residues is important for conferring PLK1 specificity. Alternatively, the presence of a glutamine residue at the À2 position could be crucial for strong Plk2-mediated interactions.
Besides each amino acid residue of the p-Thr78 peptide involved in defining the PLK1 PBD binding, the positions of the glycerol in the neighboring pocket and the network of water molecules that mediate contacts between the phosphopeptide and the PBD suggest that both the glycerol and the water molecules surrounding the phosphopeptide are important elements of PBD recognition by phosphopeptides. Furthermore, the structures of PBD S+G , PBD S , PBD PL and PBD LH were remarkably similar, hinting that the glycerol molecule and the sulfate anion that occupy the phosphopeptide binding cleft mimic the role of the SpT dipeptide.
In conclusion, our results indicate that the PLK1 PBD binding pocket accommodates (i) the core SpT motif, (ii) the N-terminal hydrophobic residue, (iii) glycerol and (iv) a network of contacting water molecules. A combination of some or all of these four elements could be used for targeted drug design. A better understanding of PBD interaction, as well as further isolation and development of PBD binding agents, would greatly facilitate the discovery of a new class of PLK1-specific anticancer therapeutic agents.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
